Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer
Background Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial. Methods We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2017-09, Vol.24 (5), p.667-672 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 5 |
| container_start_page | 667 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 24 |
| creator | Inoue, Masayuki Nakagomi, Hiroshi Nakada, Haruka Furuya, Kazushige Ikegame, Kou Watanabe, Hideki Omata, Masao Oyama, Toshio |
| description | Background
Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.
Methods
We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER
+
or PR
+
/HER2
−
subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.
Results
The clinical stage was significantly higher in the ILC patients than in the IDC (
p
= 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (
p
= 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (
p
= 0.05). In ER
+
or PR
+
/HER2
−
subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (
p
= 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (
p
|
| doi_str_mv | 10.1007/s12282-017-0753-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1861585626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712279959</galeid><sourcerecordid>A712279959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-222353134b765ffa26094527b8ffad533a1d3c8a95bf1f15c52a73b4999640b83</originalsourceid><addsrcrecordid>eNp9kUtrFjEUhoMotlZ_gBsZcONmai6Tm7tS6gUKLtR1yGROasrM5DPJFPrvPR9TRUEkgZwkz_uSnJeQl4yeM0r128o4N7ynTPdUS9EPj8gpM4b2AxfiMdZioL0yypyQZ7XeUjoITdVTcsINo8YqfUralwOEFFPoampQuxy7BZqvOHGXVpx3vqY76OY8brMvXfAlpDUv_l3nuwKt5IoW7YiE_D2X1tW2Tfd_ODV0HwtgieI1QHlOnkQ_V3jxsJ6Rb--vvl5-7K8_f_h0eXHdB0lZ6znnQgr8xKiVjNFzRe0guR4NbiYphGeTCMZbOUYWmQySey3GwVqrBjoacUbe7L6Hkn9sUJtbUg0wz36FvFXHjGLSSMUVoq939MbP4NIacys-HHF3obHN2lppkTr_B4VjgiWFvEJMeP6XgO2CgG2qBaI7lLT4cu8YdccM3Z6hwwzdMUM3oObVw6u3cYHpt-JXaAjwHah4td5Acbd5Kyt28j-uPwH726aj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1861585626</pqid></control><display><type>article</type><title>Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Inoue, Masayuki ; Nakagomi, Hiroshi ; Nakada, Haruka ; Furuya, Kazushige ; Ikegame, Kou ; Watanabe, Hideki ; Omata, Masao ; Oyama, Toshio</creator><creatorcontrib>Inoue, Masayuki ; Nakagomi, Hiroshi ; Nakada, Haruka ; Furuya, Kazushige ; Ikegame, Kou ; Watanabe, Hideki ; Omata, Masao ; Oyama, Toshio</creatorcontrib><description>Background
Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.
Methods
We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER
+
or PR
+
/HER2
−
subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.
Results
The clinical stage was significantly higher in the ILC patients than in the IDC (
p
= 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (
p
= 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (
p
= 0.05). In ER
+
or PR
+
/HER2
−
subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (
p
= 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (
p
< 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (
p
= 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy.
Conclusions
The extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-017-0753-4</identifier><identifier>PMID: 28108967</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Antineoplastic Agents, Hormonal - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer ; Cancer Research ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Ductal, Breast - secondary ; Carcinoma, Lobular - drug therapy ; Carcinoma, Lobular - mortality ; Carcinoma, Lobular - pathology ; Carcinoma, Lobular - secondary ; Comparative analysis ; Development and progression ; Disease-Free Survival ; Epidermal growth factor ; Estrogen ; Female ; Follow-Up Studies ; Hormone therapy ; Humans ; Lung Neoplasms - epidemiology ; Lung Neoplasms - pathology ; Lung Neoplasms - secondary ; Lymphatic Metastasis ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Oncology ; Oncology, Experimental ; Original Article ; Peritoneal Neoplasms - epidemiology ; Peritoneal Neoplasms - pathology ; Peritoneal Neoplasms - secondary ; Progesterone ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Surgery ; Surgical Oncology ; Treatment Outcome</subject><ispartof>Breast cancer (Tokyo, Japan), 2017-09, Vol.24 (5), p.667-672</ispartof><rights>The Japanese Breast Cancer Society 2017</rights><rights>COPYRIGHT 2017 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-222353134b765ffa26094527b8ffad533a1d3c8a95bf1f15c52a73b4999640b83</citedby><cites>FETCH-LOGICAL-c501t-222353134b765ffa26094527b8ffad533a1d3c8a95bf1f15c52a73b4999640b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-017-0753-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-017-0753-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28108967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inoue, Masayuki</creatorcontrib><creatorcontrib>Nakagomi, Hiroshi</creatorcontrib><creatorcontrib>Nakada, Haruka</creatorcontrib><creatorcontrib>Furuya, Kazushige</creatorcontrib><creatorcontrib>Ikegame, Kou</creatorcontrib><creatorcontrib>Watanabe, Hideki</creatorcontrib><creatorcontrib>Omata, Masao</creatorcontrib><creatorcontrib>Oyama, Toshio</creatorcontrib><title>Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.
Methods
We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER
+
or PR
+
/HER2
−
subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.
Results
The clinical stage was significantly higher in the ILC patients than in the IDC (
p
= 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (
p
= 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (
p
= 0.05). In ER
+
or PR
+
/HER2
−
subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (
p
= 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (
p
< 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (
p
= 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy.
Conclusions
The extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Ductal, Breast - secondary</subject><subject>Carcinoma, Lobular - drug therapy</subject><subject>Carcinoma, Lobular - mortality</subject><subject>Carcinoma, Lobular - pathology</subject><subject>Carcinoma, Lobular - secondary</subject><subject>Comparative analysis</subject><subject>Development and progression</subject><subject>Disease-Free Survival</subject><subject>Epidermal growth factor</subject><subject>Estrogen</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hormone therapy</subject><subject>Humans</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - secondary</subject><subject>Lymphatic Metastasis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Article</subject><subject>Peritoneal Neoplasms - epidemiology</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Progesterone</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtrFjEUhoMotlZ_gBsZcONmai6Tm7tS6gUKLtR1yGROasrM5DPJFPrvPR9TRUEkgZwkz_uSnJeQl4yeM0r128o4N7ynTPdUS9EPj8gpM4b2AxfiMdZioL0yypyQZ7XeUjoITdVTcsINo8YqfUralwOEFFPoampQuxy7BZqvOHGXVpx3vqY76OY8brMvXfAlpDUv_l3nuwKt5IoW7YiE_D2X1tW2Tfd_ODV0HwtgieI1QHlOnkQ_V3jxsJ6Rb--vvl5-7K8_f_h0eXHdB0lZ6znnQgr8xKiVjNFzRe0guR4NbiYphGeTCMZbOUYWmQySey3GwVqrBjoacUbe7L6Hkn9sUJtbUg0wz36FvFXHjGLSSMUVoq939MbP4NIacys-HHF3obHN2lppkTr_B4VjgiWFvEJMeP6XgO2CgG2qBaI7lLT4cu8YdccM3Z6hwwzdMUM3oObVw6u3cYHpt-JXaAjwHah4td5Acbd5Kyt28j-uPwH726aj</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Inoue, Masayuki</creator><creator>Nakagomi, Hiroshi</creator><creator>Nakada, Haruka</creator><creator>Furuya, Kazushige</creator><creator>Ikegame, Kou</creator><creator>Watanabe, Hideki</creator><creator>Omata, Masao</creator><creator>Oyama, Toshio</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer</title><author>Inoue, Masayuki ; Nakagomi, Hiroshi ; Nakada, Haruka ; Furuya, Kazushige ; Ikegame, Kou ; Watanabe, Hideki ; Omata, Masao ; Oyama, Toshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-222353134b765ffa26094527b8ffad533a1d3c8a95bf1f15c52a73b4999640b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Ductal, Breast - secondary</topic><topic>Carcinoma, Lobular - drug therapy</topic><topic>Carcinoma, Lobular - mortality</topic><topic>Carcinoma, Lobular - pathology</topic><topic>Carcinoma, Lobular - secondary</topic><topic>Comparative analysis</topic><topic>Development and progression</topic><topic>Disease-Free Survival</topic><topic>Epidermal growth factor</topic><topic>Estrogen</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hormone therapy</topic><topic>Humans</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - secondary</topic><topic>Lymphatic Metastasis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Article</topic><topic>Peritoneal Neoplasms - epidemiology</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Progesterone</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Inoue, Masayuki</creatorcontrib><creatorcontrib>Nakagomi, Hiroshi</creatorcontrib><creatorcontrib>Nakada, Haruka</creatorcontrib><creatorcontrib>Furuya, Kazushige</creatorcontrib><creatorcontrib>Ikegame, Kou</creatorcontrib><creatorcontrib>Watanabe, Hideki</creatorcontrib><creatorcontrib>Omata, Masao</creatorcontrib><creatorcontrib>Oyama, Toshio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inoue, Masayuki</au><au>Nakagomi, Hiroshi</au><au>Nakada, Haruka</au><au>Furuya, Kazushige</au><au>Ikegame, Kou</au><au>Watanabe, Hideki</au><au>Omata, Masao</au><au>Oyama, Toshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>24</volume><issue>5</issue><spage>667</spage><epage>672</epage><pages>667-672</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial.
Methods
We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor–node–metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER
+
or PR
+
/HER2
−
subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease.
Results
The clinical stage was significantly higher in the ILC patients than in the IDC (
p
= 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (
p
= 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (
p
= 0.05). In ER
+
or PR
+
/HER2
−
subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (
p
= 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (
p
< 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (
p
= 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy.
Conclusions
The extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>28108967</pmid><doi>10.1007/s12282-017-0753-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2017-09, Vol.24 (5), p.667-672 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1861585626 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Agents, Hormonal - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Cancer Research Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - secondary Carcinoma, Lobular - drug therapy Carcinoma, Lobular - mortality Carcinoma, Lobular - pathology Carcinoma, Lobular - secondary Comparative analysis Development and progression Disease-Free Survival Epidermal growth factor Estrogen Female Follow-Up Studies Hormone therapy Humans Lung Neoplasms - epidemiology Lung Neoplasms - pathology Lung Neoplasms - secondary Lymphatic Metastasis Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Oncology Oncology, Experimental Original Article Peritoneal Neoplasms - epidemiology Peritoneal Neoplasms - pathology Peritoneal Neoplasms - secondary Progesterone Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Surgery Surgical Oncology Treatment Outcome |
| title | Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Specific%20sites%20of%20metastases%20in%20invasive%20lobular%20carcinoma:%20a%20retrospective%20cohort%20study%20of%20metastatic%20breast%20cancer&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Inoue,%20Masayuki&rft.date=2017-09-01&rft.volume=24&rft.issue=5&rft.spage=667&rft.epage=672&rft.pages=667-672&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-017-0753-4&rft_dat=%3Cgale_proqu%3EA712279959%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1861585626&rft_id=info:pmid/28108967&rft_galeid=A712279959&rfr_iscdi=true |